Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Christopher Hansung Ko
|
| gptkbp:collaboratesWith |
gptkb:Organon
gptkb:Biogen gptkb:Merck_&_Co. |
| gptkbp:focusesOn |
biosimilars
biopharmaceuticals |
| gptkbp:foundedIn |
2012
|
| gptkbp:headquartersLocation |
gptkb:Incheon,_South_Korea
|
| https://www.w3.org/2000/01/rdf-schema#label |
Samsung Bioepis
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableAchievement |
first Korean company to launch biosimilars in Europe
|
| gptkbp:numberOfEmployees |
over 900
|
| gptkbp:parentCompany |
gptkb:Samsung_Biologics
Biogen (former co-owner) |
| gptkbp:products |
gptkb:Benepali
gptkb:Eticovo gptkb:Renflexis gptkb:Ontruzant gptkb:Hadlima Flixabi Imraldi |
| gptkbp:regionServed |
global
|
| gptkbp:stockExchange |
not publicly listed
|
| gptkbp:subsidiary |
gptkb:Samsung_Group
|
| gptkbp:website |
https://www.samsungbioepis.com
|
| gptkbp:bfsParent |
gptkb:Samsung_Biologics
gptkb:Renflexis gptkb:Byooviz |
| gptkbp:bfsLayer |
6
|